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Abstract
Objectives: In this study we investigated the susceptibility profiles against macrolides and lincosamides of 85 C. striatum strains isolated at a clinical centre in Sousse 
(Tunisia).
Methods: The strains were identified by the routine biochemical assays and then confirmed by Vitek-Maldi-Tof-MS. MIC’s of erythromycin and clindamycin were 
determined using the microdilution method. The detection of erm(X), erm(B), msr(A), mph(A) and mef(A-E) resistance genes was performed by PCR. The strains were 
typed by PFGE using XbaI. 
Results: Sixty-nine (81.17%) strains were resistant to erythromycin, 58 (67.44%) strains were resistant to clindamycin. There was a high correlation between the 
resistance to erythromycin and clindamycin and the presence of erm(X) gene in 85.50% and 89.65% respectively. The erm(B) gene was detected in 21(24.70%) strains 
whereas, no others genes were detected in our strains collection. By PFGE, the 85 strains belonged to 18 different clones. 
Conclusion: erm(X) is implicated in macrolide resistance for almost all the Corynebacterium strains analyzed in our study. Other resistance genes like erm(B) must 
also be implicated in this resistance, although its presence seems to be unusual in previously reported studies.
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Introduction
Corynebacterium striatum is an ubiquitous microorganism of 
the human skin and mucous membranes. However, it is a significant 
emerging opportunistic pathogen causing serious infections in 
immunocompromised and hospitalized patients and isolated as the 
etiological factor of various infections such as pneumonia vertebral 
osteomyelitis septicemia and endocarditis [1-4]. Different studies 
showed high resistance rates against several antimicrobials and many 
outbreaks of multidrug resistant C. striatum have been recently 
reported [5,6]. Macrolides are frequently used in infections that can 
be caused by these microorganisms and are an alternative to b-lactams 
and tetracycline. They act by binding to the 50S subunits of bacterial 
ribosomes and interfere with protein synthesis by inhibiting the 
elongation of peptide chains [7]. Macrolide resistance in C. striatum 
is of particular interest because it is clearly an acquired phenotype and 
is common in clinical isolates. In C. striatum, resistance to macrolides 
was previously shown to be mainly due to methylase enzymes that are 
codified by erm genes.
Other resistance mechanisms such as mutations in 23S rRNA 
domain V, modifications of proteins L4 and L22, efflux pump systems, 
and hydrolytic enzymes have been reported in different genera [8,9]. 
Several studies reported high levels of resistance to macrolides among 
Corynebacterium species [10,11,12]. However, in Tunisia, no data are 
available. Therefore, we investigated the susceptibility profiles against 
macrolides and lincosamides of 85 C. striatum strains isolated at a 
clinical centre in Sousse (Tunisia).
Materials and methods
Bacterial strains
We tested 85 C. striatum strains isolated from different specimens 
of patients presented at the laboratory of microbiology at the tertiary 
Hospital F. Hached Sousse, Tunisia, between January 2007 and 
December 2012. In this study, one isolate per patient was used. Strains 
were identified using a phenotypic method with the API Coryne 
system (bioMerieux) according to the manufacturer’s instructions 
and by comparison with the API WEB database. Strains were also 
identified using a MALDI-TOF/ VITEK MS mass spectrometry system 
(bioMerieux). Obtained spectra were analyzed with the VITEK MS 
database.
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species such as C. amycolatum, C. aurimucosum, C. minutissimum and 
C. simulans. However, in the MALDI-TOF-MS method the strains 
were identified with cut off ≥99.99. Screening test for sensitivity to 
erythromycin and clindamycin was performed using the disc diffusion 
method. MIC determinations for erythromycin and clindamycin with 
microdilution method confirmed the results of the disc diffusion 
method.
Resistance to examined antibiotics was observed in approximately 
80% of the strains, ten of which appeared to be resistant only to one 
antibiotic: seven were resistant to clindamycin, while three were 
resistant to erythromycin. Fifty-three strains showed resistance to both 
antibiotics (Table 2). The shape of the growth inhibition zones indicated 
the presence of a constitutive MLSB resistance type. 
The bacterial DNA of all 85 strains was amplified with primers for 
resistance genes to macrolide and lincosamide antibiotics. In 62 out of 
85, the erm(X) gene was present. The amplification product of erm(B) 
gene was detected in 21 C. striatum strains, and in 12 strains both erm(X) 
and erm(B) amplicons were detected. There was a high correlation 
between the resistance to erythromycin and clindamycin and the 
presence of erm(X) gene in 85.50% and 89.65% respectively (Figure 1). 
Whereas, the erm(B) gene was detected in 26.68% and 20.68% of the 
strains resistant to erythromycin and clindamycin respectively (Figure 
1). No amplification products of other tested genes were detected in 
any of the studied strains (Table 3). Although they showed resistance 
to macrolide and clindamycin, no amplification products were detected 
in 3 strains.
PFGE analysis indicated that the 85 C. striatum isolates represented 
18 distinct strain types (data not shown), with the forty ERY-susceptible 
strains being distinct from the ERY resistant strain types. Ten strains 
resistant to erythromycin, isolated from the same ward in the same 
period, belonged to the same clone.
Discussion
The genus Corynebacterium includes a high number of species that 
are usually isolated from human skin as saprophytes. However, these 
microorganisms have also been reported as infectious agents in a broad 
group of patients and have showed broad-spectrum resistance.
Antimicrobial susceptibility testing
In the screening tests for all investigated strains, inducible type of 
MLSB resistance was tested. Antibiotic discs (Biorad) of erythromycin 
(E - 15 mg) and clindamycin (Cln- 2 mg) were placed 15–20mm from 
each other on the on cation-adjusted Mueller-Hinton agar with 5% 
sheep blood and inoculums of 1.0 McFarland. The plates were incubated 
for 48 hours at 35°C. The appearance of a flattening zone around the 
clindamycin confirmed the presence of inducible resistance. In the 
case that approved breakpoints for Corynebacterium spp. were absent, 
criteria for MLSB antibiotics for Staphylococcus spp were used. The 
susceptibility to erythromycin and clindamycin was also investigated 
using microdilution method in cation adjusted Muller-Hinton broth in 
accordance with guidelines of the Clinical and Laboratory Standards 
Institute (CLSI). The minimum inhibitory concentration (MIC) was 
estimated according to the CLSI guidelines for Corynebacterium spp. 
In the absence of approved breakpoints for Corynebacterium spp, 
breakpoints reported for Staphylococcus spp were used. C. striatum 
(ATCC 6940), C. jeikeium (ATCC 43734), E. coli (ATCC 25922) and S. 
pneumoniae (ATCC 49619) and S. aureus (ATCC 29213) strains were 
used as controls. The strains were grown on blood agar plates during 
24–48 hours at 37°C in normal atmosphere and checked for purity. 
Nucleic acid extraction and PCR
Few colonies were suspended in 200 ml of Instagene matrix 
(Biorad). The bacterial suspension was incubated during 15 minutes at 
56°C followed by 8 minutes at 100°C and subsequently centrifuged at 
12,000 rpm for 3 minutes. Supernatant was used for PCR studies. PCR 
was performed using commercial KAPA2G Fast HotStart Ready Mix 
(2X). The primers used for detection of the erm(X) gene were Cerm 1 
(5’-GAC ACG GCC GTC ACG AGC AT-3’) and Cerm 2 (5’-GGC GGC 
GAG CGA CTT CC- 3’); for the erm(A) gene: Erm A-1 (5’-TCT AAA 
AAG CAT GTA AAA GAA-3’) and Erm A-2 (5’-CTT CGA TAG TTT 
ATT AAT AGT-3’); for the erm(B) gene: Erm B-1 (5’-GAA AAG GTA 
CTC AAC CAA ATA-3’) and Erm B-2 (5’-AGT AAC GGT ACT TAA 
ATT GTT TAC-3’); and for the mef(A-E) gene: Mef A-E-1 (5’-AGT 
ATC ATT ATT CAC TAG TGC-3’) and Mef A-E-2 (5’-TTC TTC TGG 
TAC TAA AAG TGG-3’) and for the mph(A) gene: MphA-1(5’-AAC 
TGT ACG CAC TTG C-3’) and MphA-2 (5’-GGT ACT CTT CGT 
TAC C-3’); and for the msrA gene: MsrA-1 (5’ GCA CTT ATT GGG 
GGT AAT GG3’) and MsrA-2 ( 5’GTC TAT AAG TGC TCT ATC GTG 
3’). The erm(X) gene amplification was performed according to the 
protocol described by Rosato, et al. [10]. For all other genes we applied 
PCR conditions previously reported for Streptococcus sp [13]. The 
amplification products were detected by electrophoresis in 2% agarose. 
The size of the amplicons was estimated using commercial molecular 
weight ladder (BioRad Laboratories, Hercules, CA). 
Pulsed-field gel electrophoresis (PFGE)
For further characterization of C. striatum isolates, we used the 
PFGE macro-restriction analysis with XbaI as previously described [5]. 
Macro-restriction fragments were separated on 1% (wt/vol) ultrapure 
agarose gels at 6V/Cm, for 18h at 14°C with pulse times of 0.1-5 s on 
CHEF-DR® III. Lambda DNA concatemers were used as molecular size 
markers. Similarities among macro-restriction pattern were identified 
according to established criteria.
Results
A total of 85 C. striatum strains were isolated from different 
specimens (Table 1). The API Coryne often provided ambiguous results 
and could not differentiate between C. striatum and other related 
Source Number of species Percentage %
Wound swab 20 23.53%
blood 3 3.53%
Eye conjunctival swab 7 8.23%
Ear swab 15 17.65%
Sputum 5 5.89%
Urine 9 10.58%
Vaginal swab 8 9.41%
Tracheostomy secretion 6 7.06%
Catheter injection site 4 4.70%
Sperm 3 3.53%
Medical devices 5 5.89%
Table 1. Isolated strains of C. striatum (n = 85) from various infection sites
Range (µg/ml) Susceptibility, number of strains (%)
Antibiotics S I R
Erythromycin 0.06-64 14 2 69
Clindamycin 0.06-64 7 20 58
Table 2. Susceptibility of 85 C. striatum strains studied to MLS antibiotics
S: Susceptible, R: Resistant, I: Intermediate
Alibi S (2019) Phenotypic and molecular characterization of resistance to macrolides and Lincosamides in Corynebacterium striatum clinical strains isolated from 
Tunisia
 Volume 4: 3-4Clin Med Invest, 2019          doi: 10.15761/CMI.1000196
In this study, including 85 strains of C. striatum derived from a 
variety of infections in humans, the use of conventional method based 
on the morphological and biochemical traits (Api Coryne strips) 
proved to be insufficient and only the application of the MALDI-TOF/
VITEK method allowed the correct identification of the strains.
The C. striatum strains studied showed high resistance to 
macrolides of (81.17%), a fact that confirms the previously reported 
high prevalence of resistance among Corynebacterium species 
[10,11,14,15]. Clindamycin showed low activity against C. striatum 
strains (67.44%). The activity of erythromycin and clindamycin was 
almost identical. Among Corynebacterium species, the most frequently 
described macrolide resistance mechanism is the presence of methylase 
enzymes codified by erm(X) class genes.
The results obtained in our study confirm the high prevalence of the 
erm(X) genes and the correlation between the presence of this amplicon 
and the MLSB phenotype was higher than 80%. Three strains showed an 
MLSB resistance phenotype despite being negative for all genes tested. 
This must be due to the presence of the other resistance mechanisms. In 
this sense, mutations in 23S rRNA domain V and alterations of protein 
L4 and L22 have originated an MLSB resistance phenotype [16-19].
The amplification products of the erm(B) gene were detected in 21 
(24.70%) strains. The presence of this gene has already been described in 
group A Corynebacterium strains [20-22]. In this study, the prevalence 
of this gene was higher than previously reported by Ortiz-Pérez, et al. 
[15] and Szemraj et al. [11].
Besides, there were 12 strains that carried the erm(X) and erm(B) 
genes simultaneously, a phenomenon previously detected in C. 
urealyticum and in Staphylococcus where the presence of several erm 
genes is very common [23].
In our study, no amplification products of the mef(A-E) gene were 
detected, although this gene has been previously reported in the genus 
Corynebacterium [22]. Other efflux pump genes such as msr have also 
been reported in this genus [24], but they were not detected in our 
report. PFGE analysis showed that the strains tested were genetically 
unrelated. The 10 resistant strains belonging to the same clone and 
isolated from the same ward in the same period suggested a clonal 
outbreak nosocomial infection.
Conclusion
According to our data erm(X) is implicated in macrolide resistance 
for almost all the C. striatum strains analyzed in our study. Other 
resistance genes like erm(B) must also be implicated in this resistance, 
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Figure 1. Distribution of erm(X) and erm(B) genes among C. striatum strains according to 
the antimicrobial agents tested: (a) Erythromycin; (b) Clindamycin
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